We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
- Recent ICPT Stock Price: $9.42
- Yearly Gain for ICPT stock: -47.00%
- Market Cap for ICPT stock: $562.78M
- P/E Ratio for ICPT stock: 1.5
Will ICPT's stock price go up? Is there an accurate ICPT stock forecast available?
TipRanks.com reports that Intercept Pharma currently has 9 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $30.14. The target pricing ranges from a high ICPT forecast of $54.00 down to a low forecast of $17.00. Intercept Pharma (ICPT)’s last closing stock price was $9.42 which would put the average price target at 115.82% upside.
In addition, TradingView issued a Sell rating for ICPT stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT stock.
Other analysts covering ICPT include:
- Edward Nash of Canaccord Genuity issued a Hold rating with the price target of $ 12 on 21 hours ago
- Ed Arce of H.C. Wainwright issued a Sell rating with the price target of $ 8 on 1 day ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 54 on 1 day ago
If you are wondering if ICPT is a good stock to buy, here are 3rd party ratings for ICPT stock:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 42% (106 out of 251)
What is the sentiment on the street regarding Intercept Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ICPT stock: Very Bullish
- Blogger Consensus for ICPT stock: Neutral
- Media Buzz for ICPT stock: Very High
- Insider Signal for ICPT stock: ―
- Investor Sentiment for ICPT stock: Very Positive
- Hedge Fund signal for ICPT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ICPT stock including scouring the social networks like ICPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ICPT stock chart >>
Summary: Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
- Recent IMVT Stock Price: $22.24
- Yearly Gain for IMVT stock: 515.28%
- Market Cap for IMVT stock: $2.76B
- P/E Ratio for IMVT stock: -13.907
Will IMVT's stock price go up? Is there an accurate IMVT stock forecast available?
TipRanks.com reports that Immunovant currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.14. The target pricing ranges from a high IMVT forecast of $31.00 down to a low forecast of $26.00. Immunovant (IMVT)’s last closing stock price was $22.24 which would put the average price target at 30.89% upside.
In addition, TradingView issued a Buy rating for IMVT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMVT stock.
Other analysts covering IMVT include:
- Yatin Suneja of Guggenheim issued a Buy rating with the price target of $ 32 on 21 hours ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 27 on 1 day ago
- Sam Slutsky of LifeSci Capital issued a Buy rating with the price target of $ 32 on 1 day ago
- Matthew Barcus of Chardan Capital issued a Buy rating with the price target of $ 32 on 1 day ago
If you are wondering if IMVT is a good stock to buy, here are 3rd party ratings for IMVT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 42% (106 out of 251)
What is the sentiment on the street regarding Immunovant? (Current ratings compiled by TipRanks.com)
- News Sentiment for IMVT stock: Very Bullish
- Blogger Consensus for IMVT stock: Bullish
- Media Buzz for IMVT stock: Medium
- Insider Signal for IMVT stock: Very Negative
- Investor Sentiment for IMVT stock: Very Positive
- Hedge Fund signal for IMVT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on IMVT stock including scouring the social networks like IMVT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IMVT stock chart >>
Summary: VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland.
- Recent VECT Stock Price: $16.50
- Yearly Gain for VECT stock: 161.03%
- Market Cap for VECT stock: $746.60M
- P/E Ratio for VECT stock: -7.631
Will VECT's stock price go up? Is there an accurate VECT stock forecast available?
TipRanks.com reports that VectivBio Holding currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $24.00. The target pricing ranges from a high VECT forecast of $30.00 down to a low forecast of $20.00. VectivBio Holding (VECT)’s last closing stock price was $16.50 which would put the average price target at 7.88% upside.
In addition, TradingView issued a Buy rating for VECT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VECT stock.
Other analysts covering VECT include:
- Thomas Smith of SVB Securities issued a Hold rating with the price target of $ 17 on 1 day ago
- Patrick Dolezal of LifeSci Capital issued a Hold rating with the price target of $ 17 on 1 day ago
- Tiago Fauth of Credit Suisse issued a Hold rating with the price target of $ 17 on 1 day ago
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $ 21 on 1 month ago
If you are wondering if VECT is a good stock to buy, here are 3rd party ratings for VECT stock:
- TipRanks.com: Hold
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 42% (106 out of 251)
What is the sentiment on the street regarding VectivBio Holding? (Current ratings compiled by TipRanks.com)
- News Sentiment for VECT stock: ―
- Blogger Consensus for VECT stock: Bullish
- Media Buzz for VECT stock: ―
- Insider Signal for VECT stock: ―
- Investor Sentiment for VECT stock: ―
- Hedge Fund signal for VECT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on VECT stock including scouring the social networks like VECT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VECT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
